X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs ALEMBIC PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA ALEMBIC PHARMA ELDER PHARMA/
ALEMBIC PHARMA
 
P/E (TTM) x -0.2 27.3 - View Chart
P/BV x 0.1 5.5 1.8% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 ELDER PHARMA   ALEMBIC PHARMA
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
ALEMBIC PHARMA
Mar-18
ELDER PHARMA/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs380645 58.9%   
Low Rs188470 40.0%   
Sales per share (Unadj.) Rs491.2166.1 295.8%  
Earnings per share (Unadj.) Rs-3.221.9 -14.5%  
Cash flow per share (Unadj.) Rs14.427.5 52.4%  
Dividends per share (Unadj.) Rs04.00 0.0%  
Dividend yield (eoy) %00.7 0.0%  
Book value per share (Unadj.) Rs376.5117.8 319.7%  
Shares outstanding (eoy) m20.54188.52 10.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.63.4 17.2%   
Avg P/E ratio x-89.325.5 -350.6%  
P/CF ratio (eoy) x19.720.3 97.2%  
Price / Book Value ratio x0.84.7 15.9%  
Dividend payout %018.3 0.0%   
Avg Mkt Cap Rs m5,833105,090 5.6%   
No. of employees `000NANA-   
Total wages/salary Rs m2,1796,228 35.0%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m10,08931,308 32.2%  
Other income Rs m25770 365.0%   
Total revenues Rs m10,34631,378 33.0%   
Gross profit Rs m-7926,431 -12.3%  
Depreciation Rs m3611,055 34.3%   
Interest Rs m2,75634 8,106.8%   
Profit before tax Rs m-3,6535,413 -67.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-81 0.0%   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m1251,204 10.4%   
Profit after tax Rs m-654,128 -1.6%  
Gross profit margin %-7.820.5 -38.2%  
Effective tax rate %-3.422.2 -15.4%   
Net profit margin %-0.613.2 -4.9%  
BALANCE SHEET DATA
Current assets Rs m9,24018,247 50.6%   
Current liabilities Rs m9,99811,235 89.0%   
Net working cap to sales %-7.522.4 -33.5%  
Current ratio x0.91.6 56.9%  
Inventory Days Days4686 54.1%  
Debtors Days Days6061 97.7%  
Net fixed assets Rs m10,12420,035 50.5%   
Share capital Rs m206377 54.6%   
"Free" reserves Rs m5,58221,824 25.6%   
Net worth Rs m7,73422,201 34.8%   
Long term debt Rs m4,8895,000 97.8%   
Total assets Rs m22,88239,411 58.1%  
Interest coverage x-0.3160.2 -0.2%   
Debt to equity ratio x0.60.2 280.7%  
Sales to assets ratio x0.40.8 55.5%   
Return on assets %11.810.6 111.4%  
Return on equity %-0.818.6 -4.5%  
Return on capital %22.319.7 113.1%  
Exports to sales %3.046.4 6.5%   
Imports to sales %0.410.5 4.1%   
Exports (fob) Rs m30714,535 2.1%   
Imports (cif) Rs m433,288 1.3%   
Fx inflow Rs m30714,722 2.1%   
Fx outflow Rs m1257,026 1.8%   
Net fx Rs m1817,696 2.4%   
CASH FLOW
From Operations Rs m11,7543,124 376.2%  
From Investments Rs m-561-8,844 6.3%  
From Financial Activity Rs m-6,7625,026 -134.5%  
Net Cashflow Rs m4,432-693 -639.2%  

Share Holding

Indian Promoters % 39.6 74.1 53.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 2.9 258.6%  
FIIs % 16.8 9.1 184.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 13.9 259.7%  
Shareholders   16,479 49,328 33.4%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   SUN PHARMA  DR. REDDYS LAB  GSK PHARMA  UNICHEM LAB  MERCK LTD  

Compare ELDER PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 42.6% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, ALEMBIC PHARMA has posted a net profit of Rs 904 m (up 42.6% YoY). Sales on the other hand came in at Rs 9 bn (up 33.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 7.1% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 7.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA - JUBILANT LIFE SCIENCES COMPARISON

COMPARE ELDER PHARMA WITH

MARKET STATS